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Summary.-Two mouse sarcomas have been used to assess the sensitivity to Adria-
mycin of tumour cells in vivo and in vitro. Both tumours were tissue-culture adapted
so that cell survival could be assayed in vitro after treatment either in vivo or in vitro.
For both tumours (WHFIB and CBSAF) cells were highly sensitive when treated in
vitro yet very resistant to treatment in vivo, whether assayed by cell survival or re-
growth delay.
Cells from both tumours treated in vitro with Adriamycin immediately after exci-
sion were slightly more resistant than the cells maintained in vitro.
However, this was not adequate to explain the marked discrepancy between in vivo
resistance and in vitro sensitivity. The discrepancy was not due to a failure of drug
delivery. Phase of cell growth was the factor most significantly affecting chemo-
sensitivity in vitro, plateau-phase cells being much more resistant than log-phase
cells.
Hypoxia was also an important factor leading to reduced chemosensitivity.
Tumour diameter, in the range 2-8 mm, did not appear to be important.
ADRIAMYCIN (ADM) is an1 anthracycline
antibiotic which is cytotoxic to several
cell lines in vitro (Kim & Kim, 1972;
Barranco et al., 1973; Harris et al., 1978;
Sutherland et al., 1979). It is effective in
the treatment of several human malignan-
cies (Carter, 1975) especially breast car-
cinomas (Bonadonna et al., 1972; Carter,
1972; Gobblieb et al., 1974a) bone and
soft-tissue sarcomas (Bonadonna et al.,
1972; Gottlieb et al., 1974b; Rosen et al.,
1974; Sutow et al., 1974) and lymphomas
(Carter & Livingstone, 1973; Benjamin
et al., 1974; Bonadonna et al., 1974).
There are situations in which the drug
can be highly cytotoxic in vitro, but in-
effective to the same cells grown as tu-
mours in vivo (Fu et al., 1979). Balconi
et al. (1973) investigated the correlation
between the response in vivo of tumours to
a number of cytotoxic drugs and their
sensitivity in vitro when grown as cell
cultures. Tumours treated with Daunoru-
bicin, an anthracycline compound related
to ADM, responded poorly in vivo despite
sensitivity when treated in vitro; the dis-
crepancy was associated with poor plasma
and tumour levels of the drug. Belli &
Piro (1977) have shown that the resistance
of V79 cells in plateau phase to ADM,
relative to log-phase cells, is related to
low intracellular levels of the drug.
Sutherland et al. (1979) showed that
EMT6 cells growing as spheroids were
much more resistant to ADM than cells
dissociated from spheroids.
In order to study the factors underlying
differences in sensitivity to ADMoftumour
cells in vivo and in vitro, we have measured
the effect of ADM on two mouse sarcomas
which have been adapted for growth in
tissue culture. We have compared the
response to ADM of these two cell lines
when growing either as tumours in miceW. M. C. MARTIN AND N. J. McNALLY
or as single cells in vitro. We have also
investigated the influence of tumour size
on response to ADM.
MATERIALS AND METHODS
Tumours.-The two tumours were derived
from poorly differentiated sarcomas arising
spontaneously in our inbred strain of mice.
Both tumours were adapted for growth in
tissue culture, as described before (George
et al., 1977) and are denoted WHFIB, a
tumour derived from a fibrosarcoma in WHT/
HtfBv mice, and CBSAF from a sarcoma in
CBA/HtfBv mice.
Cetls in vitro.-The tissue-culture-adapted
cells of the WHFIB and CBSAF tumours
were maintained in monolayer culture in
modified Minimal Essential Medium, plus
15% foetal calf serum, benzyl penicillin,
streptomycin and amphotericin B ("Com-
plete Medium"). The tumour cells were
passaged up to only 20 times in vitro, after
which a new culture was established from a
store of cells kept deep-frozen.
For treatment of cells in vitro with ADM,
they were grown either in 5cm Petri dishes or
in flasks as suspension cultures, as described
below. In the experiments using attached
cells, Petri dishes were prepared by plating
5 x 104 (for WHFIB) or 105 (for CBSAF)
heavily irradiated "feeder" cells together
with the appropriate number oflive cells, and
left overnight to attach. The "feeder" cells
increased the plating efficiency from almost
zero to 50-80%. After overnight attachment
at 37°C, medium was removed from the
dishes and ADM added at the required con-
centration in a volume of2-5 ml medium. The
cells werethen kept at 37°C in a CO2 incubator
for the required time. The drug-containing
medium was then removed and the cells
rinsed with 2 ml Hanks' balanced salt solu-
tion (HBSS). Five ml of fresh medium was
then added and the cells were incubated for
9-10 days at 37°C in an atmosphere of 5%
C02/95% air. Colonies were then stained with
methylene blue and counted.
Cells were grown in suspension in order to
study the effect of hypoxia on chemosensi-
tivity. They were grown in 250ml conical
flasks containing rotating magnetic stirrers.
The initial concentration was 2-3 x 105/ml.
Thirty to 40 h later the cells were in exponen-
tial growth, at a concentration of 6-8 x 105/
ml. The culture was then divided between
two or more flasks which had been specially
adapted so that gas could be passed over the
medium. This was either 95% N2/5% C02, or
95% air/5% CO2 for 1 h before adding the
ADM in medium which had also been ren-
dered hypoxic. ADM was added to both
hypoxic and oxic cells in the required concen-
tration in a volume of 0-5-1 ml medium, and
samples were taken at varying intervals. All
samples were centrifuged and resuspended in
fresh medium before plating the cells and
assaying for cell survival.
We wished to compare the response to
ADM of cells in the logarithmic and plateau
phases of growth. Neither cell line could be
grown to plateau phase in monolayer culture,
because the cells tended to lose contact with
the Petri dish as they reached plateau phase.
However, cells in suspension could be grown
into the plateau phase. After a "lag" phase of
about 12 h, they grew exponentially for a
further 2 days and then passed into plateau
phase for 2-3 days before degenerating.
Plateau-phase suspension cultures were there-
fore used after 3 days of growth, when the
concentration was between 8 x 105 and 1-5 x
106 cells/ml. ADM was added in 0 5 ml
medium, and samples were taken at varying
intervals, centrifuged, resuspended and
assayed for survival as above.
Methods of obtaining tumours.-Tumours
were grown either s.c. on the chest or as small
lung nodules. S.c. tumours were obtained by
first injecting 1-3 x 107 cultured cells into a
mouse, andtransplantingtheresulting tumour
7-9 days later into the required number of
mice, as described by George et al. (1977).
Tumours reached treatment size, 6-8 mm in
diameter, 12-18 days later.
In order to study the influence of tumour
size upon chemosensitivity smalllungtumours
were used. These were obtained by injecting
105 live cells together with 105 heavily
irradiated cells in a volume of0-5 ml complete
medium into the tail vein of the mouse. Mice
were subsequently killed at various times
after injection of the cells, and their lungs
fixed in 2 ml Bouin's solution and excised.
Nine days after injection lung tumours were
not visible to the naked eye, but by 14 days
30-60 tumours of diameter up to 2 mm were
visible on the pleural surface. If left intact,
the mouse would remain well for 14-16 days,
then become ill and, if not killed, would die
at 19-21 days. For ADM experiments, mice
bearing lung tumours were injected with the
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drug 14 days after inoculation of cells. Cell
survival in the tumours was then assayed in
vitro as described below.
Invivo treatment.-Theresponseoftumours
to ADM was determined either in terms of
growth delay in situ for s.c. tumours or by
measuring cell survival in vitro following
treatment in vivo for s.c. and lung tumours.
For the in vitro assay, s.c. tumours or whole
lungs were excised, minced with scissors for
about 1 min and mechanically minced for a
further 4 min in a mixture of 0.5% trypsin
and calcium-free HBSS. The suspension was
then filtered, centrifuged at 1000 rev/min for
10 min to remove the trypsin, resuspended in
medium and the concentration of intact cells
determined with a haemacytometer and a
phase-contrast microscope. The appropriate
number of test cells was put on to Petri
dishes containing "feeder" cells and colonies
were counted 9-10 days later. For lung-
tumour suspensions, the whole lungs were
excised, washed in normal saline and cell
suspensions prepared as above.
For the regrowth-delay assay, tumours
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FIG. 1. Survival of cultured WHFIB cells in
ADM; A: Varying concentrations of ADM
for 1 h. B: 05 ,ug/ml ADM for varying
times. Data points and error bars represent
means and standard errors from between
2 and 5 repeat experiments.
treated at mean diameters of 6-8 mm were
measured 3 x weekly in 3 mutually perpen-
dicular dimensions, and the time calculated
for each tumour to regrow to a geometric
mean diameter 2 mm larger than the treat-
ment size.
Pure Adriamycin powder was kindly sup-
plied by Montedison Pharmaceuticals Ltd.
Solutions of ADM in saline were prepared
immediately before use. For treatments in
vivo the drug was normally injected i.p. (i.v.
in one experiment, see Results) in a volume
of 0 01 ml/g mouse. For treatment in vitro
appropriate dilutions in complete medium
were made and the drug added to the cells at
the appropriate time.
Drug levels in tumours were determined by
a fluorometric method (modified from Chan &
Harris, 1973). An aliquot (200 ,ul) of plasma
spiked with ADM in vitro was treated with
1 ml 0-3M HCI in methanol, centrifuged, and
the clear supernatant diluted 1:3 with dis-
tilled water and fluorometrically determined.
This gave a calibration curve which was linear
from 0to20ng/ml.Tumourswerehomogenized
in distilled water 1:5 in a Potter homogenizer,
treated as above, and the ADM concentra-
tions determined fluorometrically.
RESULTS
Adriamycin oncells in vitro
Fig. 1 shows the response of WHFIB
cells in vitro to various concentrations of
ADM for 1 h (A) or to 0 5 jg/ml for up to
4-5 h (B). In this and other figures, the
lines have been fitted to the data points
by eye. Where points are shown with error
bars they represent means and standard
errors for 2-5 determinations of survival.
Points without error bars represent single
determinations. Fig. 1A shows that the
response of cells to various concentrations
of ADM for 1 h was probably biphasic,
with a resistant "tail" developing at
survival levels below 2 x 10-3. Above this
the curve was exponential with a Do of
0-11 jug/ml. There is no clear evidence
of a biphasic response to 0 5 pg/ml for
different times (Fig. IB) though there are
few data below 2 x 10-3.
Fig. 2 shows the response of CBSAF
cells exposed to various concentrations
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FIG. 2.-Survival of cultured CBSAF cells in
ADM; A: Varying concentrations of ADM
for 1 h. B: 05 ,ug/ml ADM for varying
times. Error bars, where shown, represent
standard errors ofthe mean. Points without
error bars represent single determinations.
ofADM for 1 h (A) or 0*5 ,g/ml for various
times (B). The survival curves were about
exponential down to a surviving fraction
of 10-3. Whatever the exact shape of the
survival curves, both cell lines were
extremely sensitive to ADM when treated
in vitro.
ADM on tumours in vivo
WHT mice with WHFIB tumours and
CBA mice with CBSAF tumours at
diameters of 6-8 mm were treated with
ADM given i.p. at doses from 1I3 to 18 m/g
kg. The LD50 of ADM in both strains is
about 18 mg/kg. Tumours were excised
2-44 h after drug injection and assayed for
cell survival in vitro. Fig. 3 (A and B)
shows that there was very little cell kill
in either tumour, at any drug dose or time
of excision after ADM injection.
ADM was also given i.v. at a dose of
18 mg/kg to mice bearing s.c. WHFIB
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FIG. 3.-Survival oftumour cells treated with
ADM in vivo, with the assay in vitro;
A: WHFIB s.c. tumours. B: CBSAF s.c.
tumours. C: WHFIB lung tumours. D:
CBSAF lung tumours. Doses of ADM were
as follows (mg/kg): x 18, 0 13, A 4 5,
El 3s5, 1-8, > 1*3.
tumours. Cell survivalwas still notreduced
below 30%. Thus, failure of peritoneal
absorption is not the reason for the
resistance in vivo.
In order to test for a possible tumour-
size effect on the sensitivity of tumours to
ADM, mice bearing lung tumours up to a
maximum diameter of 2 mm were treated
with 18 mg/kg of ADM. The lungs were
excised 2-24 h after the ADM was given
and cell survival in the lung tumours was
assayed in vitro (Fig. 3 (C and D). There
was still very little cell kill in either
tumour, and cell survival never fell below
30%.
Measurements of regrowth of s.c.
CBSAF tumours after injection of ADM
showed that the time taken to regrow to
2 mm above the initial diameter was 1 7
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days for controls, 1 9 days for mice
treated with 9 mg/kg and 2-6 days for
18 mg/kg, which were not significantly
different. Analysis of the time taken to
regrow to 4 mm above the treatment
diameter gave 4 1 days for 18 mg/kg ADM
compared with 2-9 days for controls, a a
delay of 1 2 days,whichwasjustsignificant. S
For the WHFIB tumour, 10 mg/kg ADM z
gave no significant growth delay either at
2 mm or 4 mm. These small delays are z
consistent with the high level of survival '
seen in vitro after treatment in vivo g
(Fig. 3).
To test the possibility that the resistance
to ADM of tumours in vivo was due to a
resistant phase in the cell cycle, WHT mice
bearing 2mm WHFIB lung nodules were
treated with either 2 injections of 9 mg/kg
ADM 8 h apart, or 3 injections of 6 mg/kg
8 and 6 h apart. In view of the probably
long tumour half-life of the drug (Siemann Fi
& Sutherland, 1979) most cycling cells
should have been exposed to the drug
when they were not in a resistant phase.
However, cell survival was still not re-
duced below 30% (data not shown).
Drug measurements
Fluorometric measurements ofthe aver-
age amount of ADM in s.c. CBSAF tu-
mours 4, 9 or 28 h after i.p. injection of
9 mg/kg of the drug gave levels of 12, 4
and 0-25 jug/g respectively. These levels
would cause massive cell kill in vitro. For °
example, a dose of 4 Htg/ml ofADM for 1 h <
to CBSAF cells would reduce survival well wr
below 10-3.
Hypoxia >
Hypoxia has been found to be a sig- '
nificant factorinreducing chemosensitivity
to bleomycin in vitro (Roizin-Towle &
Hall, 1978). The WHFIB tumour has a
hypoxic fraction of at least 50% at
diameters of 6-8 mm, and the CBSAF a
hypoxic fraction ofat least 10% (McNally,
unpublished). We therefore investigated
the effect of hypoxia on sensitivity to FI
ADM of WHFIB cells in suspension cul-
10°
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[G. 4. Survival of cultured exponentially
growing WHFIB cells in 05 ,ug/ml ADM,
in aerobic orhypoxic conditions, two experi-
ments; A and 0, hypoxic; 0 and [l,
aerobic.
100
TIME (hours)
a. 5. Survival of cultured WHFIB cells in
0-5 ,ug/ml ADM, in exponential phase (re-
drawn from Fig. 4) or plateau phase (x).
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ture. Oxic and hypoxic cells were exposed
to 0 5 jtg/ml ADM at 37°C for times up to
4.5 h. The resulting survival curves were
both biphasic (Fig. 4) with the breakpoint
occurring at about 2 h. The hypoxic cells
were more resistant than the oxic cells,
but not enough to explain the resistance
of tumour cells in vivo.
Plateau phase
When plateau-phase WHFIB cells in
suspension culture were exposed to 0 5 ,ug/
ml ADM for times up to 4-5 h, the survival
curve had a Do of 6-9 h, i.e. the cells were
very resistant (Fig. 5). The slope of the
sensitive region of the survival curve for
oxic exponential cells is in fact 15-3 times
steeper than that for plateau-phase cells.
DISCUSSION
The chemosensitivity of both tumour
cell lines in vitro is of the same order of
magnitude as that reported by Kim & Kim
(1972) for HeLa cells, Barranco et al.
(1973) for Chinese hamster ovary cells and
Belli & Piro (1977) for V79 cells. HeLa
cells, exposed to varying concentrations
of ADM for 1 h, gave a linear survival
curve with a Do of 0.1 ,ug/ml, compared
to 0-11 ,ug/ml for the sensitive phase of
the WHFIB. Chinese hamster ovary cells
and V79 cells, under the same conditions,
both gave biphasic curves similar to but
slightly more resistant than WHFIB cells.
CBSAF cells were also slightly more
resistant than WHFIB cells.
The factor which we have shown most
profoundly to influence chemosensitivity of
cells in vitro toADMistheirgrowthphase.
For plateau-phase WHFIB cells in sus-
pension culture exposed to 0 5 ,ug/ml for
various times, the exponential survival
curve had a Do of 6-9 h (Fig. 5) compared
with about 0 45 h for log-phase cells.
Similar results were obtained with V79
379A cells, which could be grown in mono-
layer culture (Martin, unpublished).
Belli & Piro (1977) using V79 cells, and
Sutherland et al. (1979) using EMT6 mam-
mary tumour cells grown into spheroids,
both found that plateau-phase cells were
significantly more resistant to ADM than
log-phase cells. Sutherland et al. (1979)
showed by fluorescence measurements
that non-dividing cells in the outer region
of the spheroid took up significantly less
drug than log-phase cells. They also found
that, after normalizing for actual drug
uptake into the cells, there was little
difference between the sensitivity of
exponential and plateau-phase cells. How-
ever, there were cells deeper in the spher-
oids, which were still more resistant, even
after normalizing for drug uptakes. Their
values for survival of dissociated EMT6
cells or whole spheroids exposed to 0 5 jug/
ml ADM for 1 h (10-3 and 0 3 respec-
tively) reflected the same degrees of sensi-
tivity in the single cells and resistance in
aggregated cells that we have found in cells
and whole tumours respectively.
Hypoxia is a factor known to affect
profoundly the radiosensitivity of tumour
cells. Were it an important factor in
chemosensitivity, the high hypoxic frac-
tion in the WHFIB tumour (50% or
more) might explain the differences in
chemosensitivity in vivo and in vitro.
Acutely hypoxic cells in vitro were more
resistant than oxic ones, but only to a
relatively small extent (Fig. 4) and not
sufficient to explain the resistance of
tumours in vivo. Harris & Shrieve (1979)
found no difference in sensitivity to ADM
in either acutely or chronically hypoxic
EMT6 cells when compared with oxic
cells, but they exposed the cells to the
drug for only up to 2 h. Our data show
that it was only after 2 h that differences in
sensitivity between oxic and hypoxic cells
cells became marked. We have since found
that WHFIB cells exposed to 95% N2/
5% CO2 for up to 24 h became progres-
sively more resistant, but still not to a
degree adequate to explain resistance of
tumours in vivo (data not shown). Smith
et al. (1980) found that hypoxic V79 cells
became much more resistant to ADM with
longer times in hypoxia. However, in these
circumstances one may be altering factors
other than the state of oxygenation of the
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cells, e.g. nutritional status, pH, or growth
fraction.
Since the sensitivity to ADM of cultured
cells in vitro differs so much from that of
the tumours in vivo, it is possible that the
cells composing the tumours had become
inherently more resistant to ADM while
growing in situ. To test this, s.c. tumours
were excised, cell suspensions prepared
and appropriate numbers plated on dishes.
These were then treated with ADM 16 h
later. Cells from both WHFIB and CBSAF
tumours gave survival curves which were
similar to the corresponding survival
curves for cultured cells, though in each
case they were slightly more resistant.
WHFIB tumour cells gave a suwvival
curve with a Do of 0-18 ,tg/ml (mean of 4
experiments) compared with 0 11 jg/ml
for cultured cells; CBSAF cells gave a sur-
vival curve with Do= 0-28 ,ug/ml, com-
pared with 0.14 jug/ml for cultured cells.
However, this increased resistance is quite
inadequate to explain the enormously
greater resistance of tumours in vivo. If
cells explanted from tumours were treated
48 h after plating, when they were in log
phase, this small resistance was lost and
they responded in the same way as the
cultured cells. Thus, the resistance to
ADM of tumours in vivo is probably not
due to an inherent resistance ofthe tumour
cells in vivo, relative to in vitro.
The demonstration that i.v. ADM did
not increase cell kill, and that reasonably
high levels ofthe drug were in the tumour,
suggest that the lack of effect on tumours
in vivo is not due to failure ofdrug delivery
to the tumour as a whole. In spite of this,
the drug is clearly not very cytotoxic in
vivo.
If drug-killed cells in tumours were be-
ing rapidly removed and therefore not
counted in the haemacytometer, this
would inflate the estimate of cell survival
in the tumour. However, in this case we
should expect a decrease in cell yield in
tumours from ADM-treated mice relative
to control mice. Since tumour half-life is
long (Siemann & Sutherland, 1979) the
in vitro data would predict a surviving
fraction below 10-3. However, survival was
always greater than 30%. A fall in cell
yield could only explain this if there were
a loss of 2-3 decades of cells, which would
certainly be detectable. In practice we
have not detected any systematic fall in
cell yield following treatment with ADM.
The slight delay in tumour growth agrees
with the high level of cell survival, and is
a further indication that this was not an
artefact due to loss of drug-killed cells.
The drug Amphotericin B (Fungizone)
was incorporated in the medium used in
these experiments at a concentration of
2-5 ,ug/ml. Hahn et al. (1977) have shown
that in HAl cells this drug caused cell
kill at high temperatures, but not at 37°C.
They suggested that this effect might be
due to the action of the drug on the cell
membrane. Therefore there is a possibility
that its presence in the medium could have
affected results by modifying the cell
membrane and restricting entry of ADM
into the cell. We feel this is unlikely for
thefollowing reasons: (1) Hahn etal. (1977)
could demonstrate the effect only at high
temperatures with higher drug concentra-
tions than ours; (2) the difference we have
seen between the response of oxic vs
hypoxic cells and plateau versus log-phase
cells occurred in cells growing in identical
media; (3) log-phaseWHFIB cells respond
to ADM in the same way, whether or not
amphotericin B is present in the medium
(data not shown).
We have found that 2mm lung tumours
are just as resistant to the drug as 6-8mm
s.c. tumours. Thus, at least in this size
range, no increase in sensitivity to ADM as
tumour size decreases is seen. This has
important implications in clinical chemo-
therapy, in which much stress is placed on
the belief that micrometastases are more
sensitive than the primary tumour. In
breast carcinoma, ADM is commonly used
in prophylactic regimes designed to treat
preclinical metastases, together with other
drugs, e.g. vincristine, methotrexate, cyclo-
phosphamide and 5-fluorouracil. "Pre-
clinical" lung metastases in the WHFIB
tumour were clearly no more sensitive
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than s.c. tumours of 50-500 times the
volume at the "primary" site. However,
this does not preclude the possibility that
in tumours which are sensitive to ADM
there is a tumour-size effect, as there is
with radiation (Shipley et al., 1975) cyclo-
phosphamide (Twentyman, 1977) and
BCNU (Steel et al., 1976).
It is possible that the same factors
which cause the cells at the centre of a
spheroid to be resistant are causing the
tumours to be resistant. If the sole reason
for resistance of tumours in vivo were that
a high proportion of their cells were not
cycling and so excluding the drug, we
would have to conclude that even in 2mm
poorly-differentiated lung tumours many
of the cells were out of cycle and so resis-
tant to the drug. Labelling studies should
give more information on this. Other fac-
tors may also prevail in the inner tumour
or spheroid to produce ADM resistance.
These may include pH changes, prolonged
hypoxia, poor nutritional status, cell con-
tact phenomena or inhibition of drug
action by the presence of breakdown
products.
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